#	Pagina
attuale pagina	/open-h2020/projects/197387/index.html
-1	/open-h2020/per-topic/microflora/list/index.html
-2	/open-h2020/per-topic/originiot/list/index.html
-3	/open-h2020/per-topic/internationally/list/index.html
-4	/open-h2020/per-topic/drum/list/index.html
-5	/open-h2020/per-topic/caep/list/index.html
-6	/open-h2020/projects/203372/index.html
-7	/open-h2020/per-topic/mpk/list/index.html

Opendata, web and dolomites

C-POC

Hyper/Hypo Coagulability Assessment Photonic Integrated Chip based Point of Care

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

C-POC project word cloud

Explore the words cloud of the C-POC project. It provides you a very rough idea of what is the project "C-POC" about.

prescribing income antifactor photonics 37 20 diagnosis pic xa hypo innovation simultaneously care assays coagulation direct diagnostic social stroke first clinical monitoring 2008 nanophotonic works adjusted screening heparins das solution events dasphotonics accurate quality anticoagulation young systemic thrombin drug causes pivotal assay capacity http ratio 2014 reduce chip tool kill poc life gains embolism sme photonic bleeding commercialise reducing employees generation pattern people survival anticoagulants thrombosis oral antithrombin patient consequently incremental opportunity biomarkers throughput validate com levels coagulability biosensors point occurrence gained natural evaluation haemorrhages 3m effectiveness consequence risk hyper pathologies healthcare company total extensively thrombotic

Project "C-POC" data sheet

The following table provides information about the project.

Coordinator	DAS PHOTONICS SL Organization address address: CALLE ISLAS CANARIAS, 6 - 8 city: VALENCIA postcode: 46023 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-07-01 to 2015-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DAS PHOTONICS SL DAS PHOTONICS SL Organization address address: CALLE ISLAS CANARIAS, 6 - 8 city: VALENCIA postcode: 46023 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALENCIA)	coordinator	50˙000.00

Map

Project objective

DAS Photonics (http://www.dasphotonics.com/) is a young SME company with about 37 employees and 3M€ total income in 2014. Since 2008 the company works in the field of nanophotonic biosensors, field where we propose the following opportunity: “Bleeding and thrombosis kill together more people than any other causes. The coagulation system, through the formation of thrombin is pivotal in these pathologies. Therefore, the main objective of the overall innovation project is to develop, validate, and commercialise a new diagnostic tool (C-POC) based on the assessment of thrombin generation and simultaneously measurement of several biomarkers of hyper/hypo coagulability using a Photonic Integrated Chip (PIC). The thrombin generation assay is completed with two different sets of measurements, natural coagulation/anticoagulation factor assays and measurement of antiThrombin/antiFactor Xa drug levels. Consequently, a common test for anticoagulants monitoring including heparins and direct oral anticoagulants will be available. PIC based solution will provide an accurate diagnostic and/or patient evaluation with capacity for cost-effective, high sample throughput screening and point-of-care diagnosis. The proposed approach will reduce the occurrence of clinical events in stroke and systemic embolism providing gains in survival and quality of life. The incremental cost-effectiveness ratio is about a 20% per quality-adjusted life year gained when compared to current prescribing pattern. As a consequence, the social costs will be also reduced by providing extensively the C-POC solution to the First Point of Healthcare reducing in this way the risk of both thrombotic events and haemorrhages.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "C-POC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "C-POC" are provided by the European Opendata Portal: CORDIS opendata.